141 related articles for article (PubMed ID: 36442964)
1. Sarcopenia and Myositis Revisited: Emerging Role of Fluorine-18 Fluorodeoxyglucose PET in Muscle Imaging.
Debs P; Al-Zaghal A; Solnes LB; Alavi A
PET Clin; 2023 Jan; 18(1):31-38. PubMed ID: 36442964
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of
Motegi SI; Fujiwara C; Sekiguchi A; Hara K; Yamaguchi K; Maeno T; Higuchi T; Hirasawa H; Kodaira S; Tomonaga H; Tsushima Y; Ishikawa O
J Dermatol; 2019 Mar; 46(3):213-218. PubMed ID: 30614031
[No Abstract] [Full Text] [Related]
3. Multiple values of
Li Y; Zhou Y; Wang Q
Clin Rheumatol; 2017 Oct; 36(10):2297-2305. PubMed ID: 28831580
[TBL] [Abstract][Full Text] [Related]
4. Detection of multiple muscle involvement in eosinophilic myositis with ¹⁸F-FDG PET/CT.
Chen SJ; Wang XY; Hua FC; Guan YH
Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1297. PubMed ID: 23624764
[No Abstract] [Full Text] [Related]
5. Comparison between skeletal muscle and adipose tissue measurements with high-dose CT and low-dose attenuation correction CT of
Albano D; Camoni L; Rinaldi R; Tucci A; Zilioli VR; Muzi C; Ravanelli M; Farina D; Coppola A; Camalori M; Giubbini R; Bertagna F
Br J Radiol; 2021 Jul; 94(1123):20200672. PubMed ID: 34106736
[TBL] [Abstract][Full Text] [Related]
6. Focal Myositis of the Leg Presenting as Fever of Unknown Origin Detected by FDG PET/CT.
Dong A; Bai Y; Wang Y
Clin Nucl Med; 2019 Mar; 44(3):251-254. PubMed ID: 30562199
[TBL] [Abstract][Full Text] [Related]
7. 18F-Fluorodeoxyglucose positron emission tomography for the assessment of myositis: a case series.
Pipitone N; Versari A; Zuccoli G; Levrini G; Macchioni P; Bajocchi G; Salvarani C
Clin Exp Rheumatol; 2012; 30(4):570-3. PubMed ID: 22703951
[TBL] [Abstract][Full Text] [Related]
8. F18-FDG PET/CT in a patient with Antisynthetase Syndrome.
Nazerani-Zemann T; Stanzel S; Gstettner C; Aigner RM; Pernthaler B
Nuklearmedizin; 2023 Apr; 62(2):73-74. PubMed ID: 36599440
[TBL] [Abstract][Full Text] [Related]
9. Utility of positron emission tomography as a new tool for muscle involvement in patients with idiopathic inflammatory myositis: a controlled study.
Bektaş M; Işık EG; Oğuz E; Kemik F; Abbasgholizadeh A; İnce B; Özkan ZG; Yalçınkaya Y; Artım-Esen B; Gül A; İnanç M
Clin Exp Rheumatol; 2024 Feb; 42(2):358-366. PubMed ID: 38293968
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET/CT in Skeletal Muscle: Pitfalls and Pathologies.
Parida GK; Roy SG; Kumar R
Semin Nucl Med; 2017 Jul; 47(4):362-372. PubMed ID: 28583276
[TBL] [Abstract][Full Text] [Related]
11. Muscle imaging in myositis: MRI, US, and PET.
Albayda J; Demonceau G; Carlier PG
Best Pract Res Clin Rheumatol; 2022 Jun; 36(2):101765. PubMed ID: 35760742
[TBL] [Abstract][Full Text] [Related]
12. Imaging in myositis: MRI or
İlgen U; Emmungil H
Clin Rheumatol; 2022 Jul; 41(7):2253-2254. PubMed ID: 35357632
[No Abstract] [Full Text] [Related]
13. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
14. Fluorine-18 labeled fluorodeoxyglucose positron emission tomography/computed tomography used in diagnosing connective tissue diseases in fever of unknown origin/inflammatory of unknown origin patients.
Chen Z; Li Y; Wang Q; Weng S; Zhou Y; Zhu J
Clin Rheumatol; 2022 Mar; 41(3):839-846. PubMed ID: 34674082
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications.
Maliha PG; Hudson M; Abikhzer G; Singerman J; Probst S
Nucl Med Commun; 2019 Apr; 40(4):377-382. PubMed ID: 30664602
[TBL] [Abstract][Full Text] [Related]
16. 2-deoxy-2-[18]fluoro-D-glucose PET/CT (18FDG PET/CT) may not be a viable biomarker in Pompe disease.
Plöckinger U; Prasad V; Ziagaki A; Tiling N; Poellinger A
Hum Genomics; 2018 Mar; 12(1):14. PubMed ID: 29523196
[TBL] [Abstract][Full Text] [Related]
17. FDG PET/CT Pitfalls in Gynecologic and Genitourinary Oncologic Imaging.
Lakhani A; Khan SR; Bharwani N; Stewart V; Rockall AG; Khan S; Barwick TD
Radiographics; 2017; 37(2):577-594. PubMed ID: 28287942
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of a [18F]-FDG PET-CT muscle-to-muscle SUV ratio for the diagnosis of active dermatomyositis.
Martis N; Viau P; Zenone T; Andry F; Grados A; Ebbo M; Castela E; Brihaye B; Denis E; Liguori S; Audemard A; Schoindre Y; Morin AS; Terrier B; Marcq L; Mounier N; Lidove O; Chaborel JP; Quinsat D
Eur Radiol; 2019 Dec; 29(12):6708-6716. PubMed ID: 31250167
[TBL] [Abstract][Full Text] [Related]
19. Focal Inflammatory Myositis on 18F-FDG PET/CT.
Bennett O; Ravi Kumar AS; Agnew J
Clin Nucl Med; 2016 Jun; 41(6):469-71. PubMed ID: 27055132
[TBL] [Abstract][Full Text] [Related]
20. Regional Variation in Skeletal Muscle and Adipose Tissue FDG Uptake Using PET/CT and Their Relation to BMI.
Goncalves MD; Green-McKenzie J; Alavi A; Torigian DA
Acad Radiol; 2017 Oct; 24(10):1288-1294. PubMed ID: 28551398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
